LIP1 Inhibitors
LIP1 inhibitors represent a class of chemical compounds designed to target a specific cellular pathway known as LIP1, short for Lipid-Induced Protein 1. This pathway is a crucial component of cellular lipid metabolism, playing a pivotal role in the regulation of lipid synthesis, storage, and utilization within the cell. LIP1 itself is a key protein within this pathway, and its activity is tightly controlled to maintain lipid homeostasis in cells. LIP1 inhibitors, therefore, aim to modulate this protein's function, primarily by reducing its enzymatic activity or altering its interactions with other cellular components.
The molecular mechanisms by which LIP1 inhibitors exert their effects can vary widely, but their common goal is to disrupt the finely-tuned balance of lipid metabolism within cells. By doing so, they have the ability to impact various cellular processes, such as energy production, membrane formation, and signaling cascades. Researchers are interested in understanding the physiological consequences of LIP1 inhibition, as it may shed light on how lipids are managed in the context of health and disease. These inhibitors are considered valuable tools in the field of cell biology and lipid research, helping scientists elucidate the intricate network of pathways that govern lipid homeostasis.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Ezetimibe | 163222-33-1 | sc-205690 sc-205690A | 25 mg 100 mg | $96.00 $241.00 | 12 | |
Ezetimibe inhibits the intestinal absorption of dietary cholesterol by blocking the NPC1L1 protein, reducing the amount of cholesterol entering the bloodstream. | ||||||
Gemfibrozil | 25812-30-0 | sc-204764 sc-204764A | 5 g 25 g | $66.00 $267.00 | 2 | |
Gemfibrozil activates PPAR-alpha, a nuclear receptor, which reduces triglyceride production and increases HDL cholesterol levels by enhancing lipoprotein lipase activity. | ||||||
Nicotinic Acid | 59-67-6 | sc-205768 sc-205768A | 250 g 500 g | $62.00 $124.00 | 1 | |
Niacin increases HDL cholesterol levels and reduces LDL cholesterol and triglycerides by inhibiting lipolysis in adipose tissue and decreasing VLDL production in the liver. | ||||||
Fenofibrate | 49562-28-9 | sc-204751 | 5 g | $41.00 | 9 | |
Fenofibrate activates PPAR-alpha, leading to decreased triglyceride synthesis and increased HDL cholesterol levels by promoting lipoprotein lipase activity. | ||||||
Lovastatin | 75330-75-5 | sc-200850 sc-200850A sc-200850B | 5 mg 25 mg 100 mg | $29.00 $90.00 $339.00 | 12 | |
Lovastatin inhibits HMG-CoA reductase, reducing the production of cholesterol in the liver and lowering LDL cholesterol levels in the bloodstream. | ||||||
Pravastatin | 81093-37-0 | sc-222188 | 50 mg | $408.00 | 1 | |
Pravastatin, like other statins, inhibits HMG-CoA reductase to decrease cholesterol synthesis, resulting in lower LDL cholesterol levels. | ||||||
Atorvastatin | 134523-00-5 | sc-337542A sc-337542 | 50 mg 100 mg | $257.00 $505.00 | 9 | |
Atorvastatin inhibits HMG-CoA reductase, reducing cholesterol production and lowering LDL cholesterol levels by promoting the uptake of LDL particles by the liver. | ||||||
Simvastatin | 79902-63-9 | sc-200829 sc-200829A sc-200829B sc-200829C | 50 mg 250 mg 1 g 5 g | $31.00 $89.00 $135.00 $443.00 | 13 | |
Simvastatin, similar to other statins, inhibits HMG-CoA reductase, leading to decreased cholesterol production and lower LDL cholesterol levels. | ||||||
Rosuvastatin | 287714-41-4 | sc-481834 | 10 mg | $145.00 | 8 | |
Rosuvastatin inhibits HMG-CoA reductase, reducing cholesterol synthesis and lowering LDL cholesterol levels, making it a potent statin agent in research. | ||||||
Bezafibrate | 41859-67-0 | sc-204650B sc-204650 sc-204650A sc-204650C | 500 mg 1 g 5 g 10 g | $31.00 $46.00 $122.00 $204.00 | 5 | |
Bezafibrate activates PPAR-alpha and PPAR-gamma receptors, leading to reduced triglycerides and increased HDL cholesterol levels through various metabolic pathways. | ||||||